Antisense oligonucleotides and their applications in rare neurological diseases

S McDowall, M Aung-Htut, S Wilton, D Li - Frontiers in neuroscience, 2024 - frontiersin.org
Rare diseases affect almost 500 million people globally, predominantly impacting children
and often leading to significantly impaired quality of life and high treatment costs. While …

Precision medicine through antisense oligonucleotide-mediated exon skipping

D Li, FL Mastaglia, S Fletcher, SD Wilton - Trends in Pharmacological …, 2018 - cell.com
Clinical implementation of two recently approved antisense RNA therapeutics–Exondys51®
to treat Duchenne muscular dystrophy (Duchenne MD) and Spinraza® as a treatment for …

Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing

BT Le, S Paul, K Jastrzebska… - Proceedings of the …, 2022 - National Acad Sciences
Recent advances in drug development have seen numerous successful clinical translations
using synthetic antisense oligonucleotides (ASOs). However, major obstacles, such as …

Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era

D Li, FL Mastaglia, S Fletcher… - Medicinal Research …, 2020 - Wiley Online Library
Parkinson's disease (PD) is one of the most common neurodegenerative disorders that
manifest various motor and nonmotor symptoms. Although currently available therapies can …

Thrombin binding aptamer G-quadruplex stabilized by pyrene-modified nucleotides

M Kovačič, P Podbevšek… - Nucleic Acids …, 2020 - academic.oup.com
Guanine-rich regions of the human genome can adopt non-canonical secondary structures.
Their role in regulating gene expression has turned them into promising targets for …

Antisense oligonucleotide-mediated splice switching: potential therapeutic approach for cancer mitigation

P Raguraman, AA Balachandran, S Chen… - Cancers, 2021 - mdpi.com
Simple Summary Splicing is an important mechanism by which precursor mRNA is modified
into mature mRNA. This splicing plays a major role in the generation of different proteins …

Recent advances in nucleic acid targeting probes and supramolecular constructs based on pyrene-modified oligonucleotides

OA Krasheninina, DS Novopashina, EK Apartsin… - Molecules, 2017 - mdpi.com
In this review, we summarize the recent advances in the use of pyrene-modified
oligonucleotides as a platform for functional nucleic acid-based constructs. Pyrene is of …

Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro

S Chen, BT Le, M Chakravarthy, TR Kosbar… - Scientific Reports, 2019 - nature.com
Antisense oligonucleotide (AO)-mediated splice modulation has been established as a
therapeutic approach for tackling genetic diseases. Recently, Exondys51, a drug that aims to …

Rational design of short locked nucleic acid-modified 2′-O-methyl antisense oligonucleotides for efficient exon-skipping in vitro

BT Le, AM Adams, S Fletcher, SD Wilton… - … Therapy-Nucleic Acids, 2017 - cell.com
Locked nucleic acid is a prominent nucleic acid analog with unprecedented target binding
affinity to cDNA and RNA oligonucleotides and shows remarkable stability against nuclease …

Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes

BT Le, K Murayama, F Shabanpoor, H Asanuma… - RSC …, 2017 - pubs.rsc.org
Serinol nucleic acid (SNA) is a novel nucleic acid analogue that can form highly stable
heteroduplexes with complementary DNA and RNA sequences. Structurally, SNA is a close …